Regencell Common Stock vs Short Term Debt Analysis

RGC Stock

USD 5.91 0.04 0.68%

Regencell Bioscience financial indicator trend analysis is much more than just breaking down Regencell Bioscience prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regencell Bioscience is a good investment. Please check the relationship between Regencell Bioscience Common Stock and its Short Term Debt accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

Common Stock vs Short Term Debt

Common Stock vs Short Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regencell Bioscience Common Stock account and Short Term Debt. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Regencell Bioscience's Common Stock and Short Term Debt is 0.92. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Regencell Bioscience Holdings, assuming nothing else is changed. The correlation between historical values of Regencell Bioscience's Common Stock and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Regencell Bioscience Holdings are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Common Stock i.e., Regencell Bioscience's Common Stock and Short Term Debt go up and down completely randomly.

Correlation Coefficient

0.92

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Common Stock

Short Term Debt

Most indicators from Regencell Bioscience's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regencell Bioscience current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

At present, Regencell Bioscience's Enterprise Value Over EBITDA is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 8.06, whereas Selling General Administrative is forecasted to decline to about 3.5 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	7.6M	6.3M	4.0M	3.8M
Cost Of Revenue	604.4K	769.7K	745.6K	708.3K

Total Operating Expenses Cost Of Revenue

Regencell Bioscience fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Net Receivables	Common Stock
Total Assets		0.95	0.96	0.99	-0.51	0.98	-0.38	0.92	0.87	-0.64	0.94	1.0	0.79	0.94	-0.41	0.99	0.91	0.95	0.6	0.18	0.95	0.99	0.91	-0.1	0.96	0.99
Short Long Term Debt Total	0.95		0.84	0.98	-0.76	0.88	-0.13	1.0	0.76	-0.52	0.82	0.95	0.93	0.82	-0.27	0.94	0.99	0.99	0.49	0.05	1.0	0.92	0.73	0.1	0.98	0.93
Other Current Liab	0.96	0.84		0.91	-0.3	0.99	-0.59	0.81	0.82	-0.74	0.95	0.96	0.6	0.95	-0.55	0.97	0.78	0.84	0.61	0.16	0.85	0.95	0.96	-0.31	0.86	0.98
Total Current Liabilities	0.99	0.98	0.91		-0.63	0.94	-0.24	0.96	0.86	-0.54	0.9	0.99	0.87	0.9	-0.31	0.97	0.96	0.98	0.54	0.19	0.98	0.97	0.84	0.02	0.99	0.97
Total Stockholder Equity	-0.51	-0.76	-0.3	-0.63		-0.36	-0.45	-0.8	-0.32	0.07	-0.31	-0.52	-0.9	-0.31	-0.13	-0.49	-0.82	-0.74	-0.08	0.19	-0.75	-0.47	-0.13	-0.5	-0.68	-0.47
Property Plant And Equipment Net	0.98	0.88	0.99	0.94	-0.36		-0.55	0.85	0.82	-0.73	0.94	0.98	0.65	0.94	-0.53	0.99	0.82	0.87	0.64	0.16	0.89	0.96	0.95	-0.27	0.89	0.99
Current Deferred Revenue	-0.38	-0.13	-0.59	-0.24	-0.45	-0.55		-0.08	-0.25	0.65	-0.48	-0.38	0.24	-0.47	0.74	-0.44	-0.04	-0.12	-0.39	-0.06	-0.14	-0.37	-0.62	0.86	-0.14	-0.46
Net Debt	0.92	1.0	0.81	0.96	-0.8	0.85	-0.08		0.73	-0.49	0.78	0.93	0.94	0.78	-0.24	0.91	1.0	0.99	0.47	0.02	1.0	0.89	0.69	0.13	0.97	0.9
Retained Earnings	0.87	0.76	0.82	0.86	-0.32	0.82	-0.25	0.73		-0.45	0.89	0.86	0.69	0.89	-0.17	0.83	0.73	0.79	0.52	0.47	0.78	0.9	0.87	0.06	0.85	0.83
Accounts Payable	-0.64	-0.52	-0.74	-0.54	0.07	-0.73	0.65	-0.49	-0.45		-0.61	-0.65	-0.22	-0.61	0.76	-0.69	-0.45	-0.47	-0.62	0.28	-0.52	-0.58	-0.7	0.45	-0.47	-0.7
Cash	0.94	0.82	0.95	0.9	-0.31	0.94	-0.48	0.78	0.89	-0.61		0.93	0.63	1.0	-0.49	0.93	0.77	0.83	0.51	0.28	0.84	0.98	0.92	-0.2	0.85	0.93
Non Current Assets Total	1.0	0.95	0.96	0.99	-0.52	0.98	-0.38	0.93	0.86	-0.65	0.93		0.79	0.93	-0.41	1.0	0.91	0.95	0.61	0.17	0.96	0.98	0.91	-0.1	0.96	0.99
Non Currrent Assets Other	0.79	0.93	0.6	0.87	-0.9	0.65	0.24	0.94	0.69	-0.22	0.63	0.79		0.63	0.04	0.75	0.95	0.93	0.31	0.1	0.92	0.77	0.5	0.41	0.91	0.73
Cash And Short Term Investments	0.94	0.82	0.95	0.9	-0.31	0.94	-0.47	0.78	0.89	-0.61	1.0	0.93	0.63		-0.49	0.93	0.77	0.82	0.51	0.27	0.84	0.98	0.92	-0.19	0.85	0.93
Good Will	-0.41	-0.27	-0.55	-0.31	-0.13	-0.53	0.74	-0.24	-0.17	0.76	-0.49	-0.41	0.04	-0.49		-0.47	-0.21	-0.23	-0.32	0.12	-0.27	-0.41	-0.48	0.8	-0.22	-0.48
Common Stock Shares Outstanding	0.99	0.94	0.97	0.97	-0.49	0.99	-0.44	0.91	0.83	-0.69	0.93	1.0	0.75	0.93	-0.47		0.89	0.93	0.61	0.14	0.94	0.97	0.91	-0.17	0.94	1.0
Non Current Liabilities Total	0.91	0.99	0.78	0.96	-0.82	0.82	-0.04	1.0	0.73	-0.45	0.77	0.91	0.95	0.77	-0.21	0.89		0.99	0.42	0.03	0.99	0.88	0.66	0.17	0.96	0.88
Inventory	0.95	0.99	0.84	0.98	-0.74	0.87	-0.12	0.99	0.79	-0.47	0.83	0.95	0.93	0.82	-0.23	0.93	0.99		0.44	0.15	0.99	0.92	0.75	0.1	0.98	0.92
Other Current Assets	0.6	0.49	0.61	0.54	-0.08	0.64	-0.39	0.47	0.52	-0.62	0.51	0.61	0.31	0.51	-0.32	0.61	0.42	0.44		-0.09	0.49	0.54	0.69	-0.09	0.54	0.62
Other Stockholder Equity	0.18	0.05	0.16	0.19	0.19	0.16	-0.06	0.02	0.47	0.28	0.28	0.17	0.1	0.27	0.12	0.14	0.03	0.15	-0.09		0.08	0.26	0.29	-0.14	0.22	0.14
Total Liab	0.95	1.0	0.85	0.98	-0.75	0.89	-0.14	1.0	0.78	-0.52	0.84	0.96	0.92	0.84	-0.27	0.94	0.99	0.99	0.49	0.08		0.93	0.75	0.09	0.98	0.93
Total Current Assets	0.99	0.92	0.95	0.97	-0.47	0.96	-0.37	0.89	0.9	-0.58	0.98	0.98	0.77	0.98	-0.41	0.97	0.88	0.92	0.54	0.26	0.93		0.91	-0.1	0.94	0.97
Short Term Debt	0.91	0.73	0.96	0.84	-0.13	0.95	-0.62	0.69	0.87	-0.7	0.92	0.91	0.5	0.92	-0.48	0.91	0.66	0.75	0.69	0.29	0.75	0.91		-0.29	0.79	0.92
Intangible Assets	-0.1	0.1	-0.31	0.02	-0.5	-0.27	0.86	0.13	0.06	0.45	-0.2	-0.1	0.41	-0.19	0.8	-0.17	0.17	0.1	-0.09	-0.14	0.09	-0.1	-0.29		0.1	-0.19
Net Receivables	0.96	0.98	0.86	0.99	-0.68	0.89	-0.14	0.97	0.85	-0.47	0.85	0.96	0.91	0.85	-0.22	0.94	0.96	0.98	0.54	0.22	0.98	0.94	0.79	0.1		0.93
Common Stock	0.99	0.93	0.98	0.97	-0.47	0.99	-0.46	0.9	0.83	-0.7	0.93	0.99	0.73	0.93	-0.48	1.0	0.88	0.92	0.62	0.14	0.93	0.97	0.92	-0.19	0.93

Click cells to compare fundamentals

Regencell Bioscience Account Relationship Matchups

Regencell Bioscience fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	514.0K	340.1K	18.0M	12.6M	8.4M	8.0M
Short Long Term Debt Total	3.1M	3.7M	771.3K	463.7K	85.7K	81.5K
Total Current Liabilities	3.2M	4.3M	577.8K	606.9K	193.6K	183.9K
Total Stockholder Equity	(2.7M)	(4.0M)	17.1M	12.0M	8.2M	8.6M
Net Debt	2.7M	3.6M	(5.6M)	(1.1M)	(2.9M)	(2.7M)
Retained Earnings	(2.7M)	(4.0M)	(11.4M)	(17.3M)	(21.6M)	(20.5M)
Cash	387.0K	59.4K	6.4M	1.6M	3.0M	2.8M
Non Current Assets Total	127.0K	273.3K	1.6M	1.0M	324.2K	308.0K
Cash And Short Term Investments	387.0K	59.4K	16.4M	11.6M	8.0M	7.6M
Liabilities And Stockholders Equity	514.0K	340.1K	18.0M	12.6M	8.4M	8.0M
Non Current Liabilities Total	3.1M	3.7M	360.3K	25.4K	25.9K	24.6K
Total Liab	3.2M	4.3M	938.0K	632.3K	219.5K	208.5K
Total Current Assets	387.0K	66.8K	16.4M	11.6M	8.1M	7.7M
Short Term Debt	3.1M	3.7M	411.0K	438.3K	59.8K	56.8K
Net Invested Capital	419.0K	(315.7K)	17.1M	12.0M	8.2M	6.9M
Net Working Capital	(2.8M)	(4.3M)	15.9M	11.0M	7.9M	4.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:

How To Invest In Regencell

Details

Is Regencell Stock a good investment?

Details

What is Regencell Bioscience's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.33)

Return On Assets

(0.28)

Return On Equity

(0.43)

The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regencell Common Stock vs Short Term Debt Analysis

Common Stock vs Short Term Debt

Common Stock vs Short Term Debt Correlation Analysis

Correlation Coefficient

Common Stock

Short Term Debt

Regencell Bioscience fundamental ratios Correlations

Regencell Bioscience Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regencell Bioscience fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Net Debt	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Short Long Term Debt Total
Non Current Liabilities Total	+ 1.0	Net Debt
Total Liab	+ 1.0	Net Debt
Cash And Short Term Investments	+ 1.0	Cash

Non Currrent Assets Other	- 0.9	Total Stockholder Equity
Non Current Liabilities Total	- 0.82	Total Stockholder Equity
Net Debt	- 0.8	Total Stockholder Equity
Total Stockholder Equity	- 0.76	Short Long Term Debt Total
Total Liab	- 0.75	Total Stockholder Equity
Inventory	- 0.74	Total Stockholder Equity